[go: up one dir, main page]

DE68905161D1 - Den blutcholesterinspiegel senkende arzneimittel. - Google Patents

Den blutcholesterinspiegel senkende arzneimittel.

Info

Publication number
DE68905161D1
DE68905161D1 DE8989312031T DE68905161T DE68905161D1 DE 68905161 D1 DE68905161 D1 DE 68905161D1 DE 8989312031 T DE8989312031 T DE 8989312031T DE 68905161 T DE68905161 T DE 68905161T DE 68905161 D1 DE68905161 D1 DE 68905161D1
Authority
DE
Germany
Prior art keywords
lowing
medicines
cholesterol level
blood cholesterol
blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE8989312031T
Other languages
English (en)
Other versions
DE68905161T2 (de
Inventor
Alfred W Alberts
Edward M Scolnick
Arnold J Repta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Application granted granted Critical
Publication of DE68905161D1 publication Critical patent/DE68905161D1/de
Publication of DE68905161T2 publication Critical patent/DE68905161T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE8989312031T 1988-11-21 1989-11-20 Den blutcholesterinspiegel senkende arzneimittel. Expired - Fee Related DE68905161T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/274,173 US4997658A (en) 1988-11-21 1988-11-21 Method for enhancing the lowering of plasma cholesterol levels

Publications (2)

Publication Number Publication Date
DE68905161D1 true DE68905161D1 (de) 1993-04-08
DE68905161T2 DE68905161T2 (de) 1993-08-26

Family

ID=23047096

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8989312031T Expired - Fee Related DE68905161T2 (de) 1988-11-21 1989-11-20 Den blutcholesterinspiegel senkende arzneimittel.

Country Status (6)

Country Link
US (1) US4997658A (de)
EP (1) EP0375156B1 (de)
JP (1) JPH0699327B2 (de)
CA (1) CA2003385A1 (de)
DE (1) DE68905161T2 (de)
LV (1) LV5785B4 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225202A (en) * 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions
HU9203780D0 (en) * 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US6080428A (en) 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US20060263428A1 (en) * 1993-09-20 2006-11-23 Eugenio Cefali Methods for treating hyperlipidemia with intermediate release nicotinic acid compositions having unique biopharmaceutical characteristics
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US6676967B1 (en) 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US6129930A (en) 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
EP0807435A3 (de) * 1996-05-17 1999-02-24 Sertürner Arzneimittel GmbH Indirekter HMG-CoA-Reduktase-Hemmer
SE9603667D0 (sv) * 1996-10-08 1996-10-08 Astra Ab Pharmaceutical compositions
KR100213895B1 (ko) * 1996-10-14 1999-08-02 박원훈 감귤류 과피 추출물, 이로부터 분리 정제된 헤스페리딘 또는 나린진을 포함하는 심혈관 질환 예방및 치료제 조성물
US20040029962A1 (en) * 1997-12-12 2004-02-12 Chih-Ming Chen HMG-COA reductase inhibitor extended release formulation
US8679534B2 (en) * 1997-12-12 2014-03-25 Andrx Labs, Llc HMG-CoA reductase inhibitor extended release formulation
WO2000018396A1 (fr) * 1998-09-25 2000-04-06 Sankyo Company, Limited PREPARATIONS A BASE D'INHIBITEUR DE HMG-CoA
US20020169145A1 (en) * 1998-10-14 2002-11-14 Rajen Shah Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent
US6569461B1 (en) * 1999-03-08 2003-05-27 Merck & Co., Inc. Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
NZ518822A (en) * 1999-11-04 2004-12-24 Andrx Corp Treating a mammal with an APP processing disorder such as Alzheimer's Disease and Down's Syndrome by administering at least one HMG-CoA reductase inhibitor
US20020107173A1 (en) * 1999-11-04 2002-08-08 Lawrence Friedhoff Method of treating amyloid beta precursor disorders
US6242003B1 (en) 2000-04-13 2001-06-05 Novartis Ag Organic compounds
US20060127474A1 (en) * 2001-04-11 2006-06-15 Oskar Kalb Pharmaceutical compositions comprising fluvastatin
US20040180087A1 (en) * 2001-06-21 2004-09-16 Boyong Li Stable controlled release pharmaceutical compositions containing pravastatin
EP1404301A4 (de) * 2001-06-21 2006-03-22 Andrx Pharmaceuticals Inc Pravastatin enthaltende stabile pharmazeutische zusammensetzungen mit kontrollierter freisetzung
AU2002366444A1 (en) * 2001-11-08 2003-09-09 Merck & Co., Inc. Compounds useful in the treatment of anthrax
EP1905431A1 (de) * 2002-01-11 2008-04-02 Circ Pharma Research and Development Limited Pharmazeutische Pravastatin-Formulierungen und Verfahren zu ihrer Verwendung
AU2003201735B2 (en) * 2002-01-11 2008-11-13 Circ Pharma Research And Development Limited Pravastatin pharmaceutical formulations and methods of their use
EP1551356A2 (de) * 2002-09-03 2005-07-13 Biovail Laboratories Incorporated Pravastatin zubereitungen und deren verwendung
SI21400A (sl) * 2003-02-12 2004-08-31 LEK farmacevtska družba d.d. Stabilna farmacevtska oblika z inhibitorjem HMG-CoA reduktaze
AU2005247195A1 (en) * 2004-05-27 2005-12-08 Dexcel Pharma Technologies Ltd Localized controlled absorption of statins in the gastrointestinal tract for achieving high blood levels of statins
AU2005305459A1 (en) * 2004-11-22 2006-05-26 Dexcel Pharma Technologies Ltd. Controlled absorption of statins in the intestine
AU2006228525A1 (en) * 2005-03-28 2006-10-05 Dexcel Pharma Technologies Ltd. Controlled absorption of statins in the intestine
US20100055173A1 (en) * 2006-10-10 2010-03-04 Adel Penhasi Release of statins in the intestine
KR100836960B1 (ko) 2007-09-07 2008-06-10 주식회사 서울제약 새로운 나이아신 제어방출형 제제
KR20200066690A (ko) 2017-10-16 2020-06-10 칭화대학교 메발로네이트 경로 억제제 및 이의 약제학적 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3538214A (en) * 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4256108A (en) * 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4160452A (en) * 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4285987A (en) * 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4200098A (en) * 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4612008A (en) * 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4755180A (en) * 1986-06-16 1988-07-05 Alza Corporation Dosage form comprising solubility regulating member
ZA874487B (en) * 1986-06-23 1987-12-23 Merck & Co.,Inc. Novel hmg-coa reductase inhibitors
CA1331563C (en) * 1987-08-03 1994-08-23 Gaylen M. Zentner Device for the controlled release of drugs with donnan-like modulation by charged insoluble resins
US4863957A (en) * 1987-12-21 1989-09-05 Rorer Pharmaceutical Corporation Novel HMG-CoA reductase inhibitors
US4900754A (en) * 1987-12-21 1990-02-13 Rorer Pharmaceutical Corp. HMG-COA reductase inhibitors
US4892884A (en) * 1987-12-21 1990-01-09 Rorer Pharmaceutical Corporation Novel hmg-coa reductase inhibitors

Also Published As

Publication number Publication date
US4997658A (en) 1991-03-05
LV5785A4 (lv) 1997-02-20
CA2003385A1 (en) 1990-05-21
JPH02237937A (ja) 1990-09-20
DE68905161T2 (de) 1993-08-26
LV5785B4 (lv) 1997-08-20
EP0375156A2 (de) 1990-06-27
JPH0699327B2 (ja) 1994-12-07
EP0375156A3 (en) 1990-12-12
EP0375156B1 (de) 1993-03-03

Similar Documents

Publication Publication Date Title
DE68905161D1 (de) Den blutcholesterinspiegel senkende arzneimittel.
DE68905249D1 (de) Blutbehaelter.
DE69018647D1 (de) Arzneimittel.
DE3783437D1 (de) Heilmittel.
NO901158L (no) Blodtrykk-overvaakningskateter.
DE3871735D1 (de) Blutfilter.
DE68917895D1 (de) Katheter.
DE68924604D1 (de) Kanüleneinsteckteil.
FI875326L (fi) Ljusbestraolningsanordning foer medicinal vaord av oera.
FI881177A (fi) Anordning foer positionering av en patient i en medicinsk panoramaroentgenfotograferingsanordning.
FI885026L (fi) Haorvaordsmedel.
FI884844L (fi) Sanitetsmedel.
FI914213A0 (fi) Anordning foer foerflyttande av patient.
FI893340A0 (fi) Foerfarande foer att erhaolla farmaceutiska sammansaettningar foer att hindra smittbara koenssjukdomar.
DE68920797D1 (de) Herzmittel.
FI893835L (fi) Laekemedel.
FI884048A (fi) Foerfarande foer bestaemning av halten av en gaskomponent i en patients andningsluft.
FI891245L (fi) Starka soetningsmedel.
DE3784595D1 (de) Arzneimittel gegen feste tumoren.
FI905236A0 (fi) Deoxiribonukleosider innehaollande farmaceutiska konsistenser foer laekning av saor.
FI896174A0 (fi) Spektriskt effektivt foerfarande foer foermedlande av den informationssignal.
FI875616A0 (fi) Farmaceutiska blandningar.
FI880363L (fi) Avbrytning av en stroemkrets foer en kondensator.
DE3878494D1 (de) Mittel gegen zuckerkrankheit.
FI912644A0 (fi) Antimikrobiskt medel.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee